<DOC>
	<DOCNO>NCT01962974</DOCNO>
	<brief_summary>This Phase 3b , multicenter study efficacy golimumab 2 mg/kg IV subject active rheumatoid arthritis receive methotrexate inadequate disease control ( define erythrocyte sedimentation rate [ ESR ] -based Disease Activity Score 28 joint [ DAS28 ] ≥ 3.2 ≥ 4 swollen ≥ 4 tender joint ) despite current anti-TNFα therapy infliximab 2 - 4 mg/kg every 4 week , 2 - 5 mg/kg every 5 week , 3 - 6 mg/kg every 6 week , 3 - 7mg/kg every 7 week , 4 - 8 mg/kg every 8 week . To eligible participation , subject must previously demonstrate initial and/or temporary improvement disease sign symptom , since exhibit diminish response despite continued treatment . It estimate 200 subject enrol study approximately 85 global site .</brief_summary>
	<brief_title>A Golimumab Phase 3b , Multicenter , Assessment Intravenous Efficacy Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab ( REMICADE® )</brief_title>
	<detailed_description>The study employ open-label `` active switch '' design move subject infliximab golimumab 2 mg/kg IV . In general , subject eligible study include men woman currently receive infliximab actual clinical practice least 18 year age active rheumatoid arthritis , previously demonstrate initial and/or temporary improvement disease sign symptom , exhibit diminished response inadequate disease control despite continued treatment . Subjects must receive infliximab combination methotrexate minimum 9 month prior first screen visit . The screen visit occur sometime Week -12 Week -10 . Consenting subject meet screen criterion receive final dose infliximab Week -8 part actual clinical practice . Golimumab IV treatment , supply sponsor , receive Weeks 0 , 4 , 12 , 20 , 28 . The primary endpoint Week 24 , final efficacy assessment Week 32 , follow-up safety assessment telephone Week 44 . There maximum 36 week last infliximab infusion Week -8 last infusion golimumab Week 28 . The duration study participation expect maximum 56 week ( include Screening Period , 32 week golimumab treatment assessment , 12-week safety follow-up ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Major Inclusion Criteria include ( limited ) : Have diagnosis Rheumatoid Arthritis ( accord revise 1987 criterion American Rheumatism Association ) . Treatment infliximab methotrexate &gt; = 9 month , ( stable dos methotrexate last 16 week 7.5 mg/week 25 mg/week ) ( antiTNFα therapy infliximab 2 4 mg/kg every 4 week , 2 5 mg/kg every 5 week , 3 6 mg/kg every 6 week , 3 7mg/kg every 7 week , 4 8 mg/kg every 8 week ) . Disease Activity Score 28 ( DAS28 ) ≥ 3.2 base Erythrocyte Sedimentation Rate ( ESR ) Week 8 Week 0 . Swollen joint count ( SJC ) ≥ 4 tender joint count ( TJC ) ≥ 4 Week 8 Week 0 . Prior response confirm physician . Major Exclusion Criteria include ( limited ) : Have history latent active granulomatous infection , include histoplasmosis , Have history latent active granulomatous infection , include histoplasmosis , coccidioidomycosis , prior first screen visit Screening Period . Have Bacille CalmetteGuérin ( BCG ) vaccination within 12 month screen . Have chest radiograph within 3 month prior first administration study agent show abnormality suggestive malignancy current active infection , include tuberculosis ( TB ) , histoplasmosis , coccidioidomycosis . Have previously receive 1 currently approve subcutaneous ( SC ) administer antiTNFα agent , etanercept , certolizumab pegol , golimumab , adalimumab . Are pregnant , nursing , plan pregnancy father child within 6 month receive last administration study agent . Weight le 35 kg great 110 kg ( le 77 pound great 242 pound ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>76 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Arthritis , Rheumatoid</keyword>
</DOC>